Efficacy of IVC injection in the treatment of ROP
Reviewed by Jonathan Chan

This is a retrospective consecutive case series of patients who received intravitreal conbercept (IVC) as a primary treatment from June 2015 to July 2016 for treatment of retinopathy of prematurity (ROP). Forty-eight eyes of 24 patients were included in the study; nine eyes in zone one, 38 eyes in zone 2 and two eyes in the aggressive posterior ROP (APROP) group. Of these, 40 eyes (83.3%) received only one injection of IVC, and the regression of plus disease occurred at a mean of 3.5 weeks +/-1.5 weeks after the first IVC. Eight of 48 eyes (16.7%) recurred, four received second IVC and four had laser treatment and the regression occurred in three weeks. In this study, the mean gestational age was 28.5 weeks, mean birth weight was 1209gm, the mean postmenstrual age (PMA) of first IVC was 34.2 weeks and the mean follow-up period was 31 weeks. No complications were observed in this study. The authors concluded that IVC is an effective treatment of ROP and larger randomised, prospective trials are needed in the future.

Efficacy of intravitreal conbercept (IVC) injection in the treatment of retinopathy of prematurity (ROP).
Bai Y, Nie H, Wei S, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2019;103:494-8.